Biotechs buck a sluggish IPO market, but investors should tread warily
While a number of IPOs have been pulled or delayed in 2026, the biotech sector has bucked the trend, with 26 companies debuting in U.S. markets.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
